Systemic and ocular safety of bevacizumab gamma: Pooled analysis of 432 eyes with neovascular age-related macular degeneration (nAMD) across the NORSE clinical programme
Purpose: To analyse pooled safety data of intravitreal bevacizumab gamma across all trials included within the NORSE clinical programme for nAMD. Methods: Post-hoc safety analysis included all eyes receiving ≥1 intravitreal injection of bevacizumab gamma for nAMD across the NORSE clinical [for full text, please go to the a.m. URL]
Authors
- Ramin Khoramnia (ORCID: https://orcid.org/0000-0002-6237-7773)
- Jakob Siedlecki
- Ulrich Thelen
Institutions
- LMU Klinikum (DE)
- Konrad-Adenauer-Stiftung (DE)
- University Hospital Carl Gustav Carus (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2026-06-17
- DOI
- https://doi.org/10.3205/26doc034
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00